These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33537001)

  • 1. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N; Reidy-Lagunes D
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.
    Yang KC; Kalloger SE; Aird JJ; Lee MKC; Rushton C; Mungall KL; Mungall AJ; Gao D; Chow C; Xu J; Karasinska JM; Colborne S; Jones SJM; Schrader J; Morin RD; Loree JM; Marra MA; Renouf DJ; Morin GB; Schaeffer DF; Gorski SM
    Cell Rep; 2021 Oct; 37(2):109817. PubMed ID: 34644566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
    Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
    Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of spontaneous pancreatic neuroendocrine tumors.
    Yu R
    Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the management of pancreatic neuroendocrine tumors.
    Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW
    Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
    Yan J; Yu S; Jia C; Li M; Chen J
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
    Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
    Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is new in the pathology of pancreatic neuroendocrine tumors?].
    Komminoth P; Perren A
    Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.